Production of Furanones
    32.
    发明申请
    Production of Furanones 审中-公开
    呋喃酮的生产

    公开(公告)号:US20080167373A1

    公开(公告)日:2008-07-10

    申请号:US12051392

    申请日:2008-03-19

    CPC classification number: C08F20/00 A01N43/08 C07D307/58 C08F24/00

    Abstract: The present invention relates to the side chain functionalization of fimbrolides (halogenated 3-alkyl-5-methylene-2(5H)-furanones) and their synthetic analogues, that yields fimbrolides substituted with a halogen, an oxygen or a nitrogen functionality in the alkyl chain, especially fimbrolide alcohols, caboxylate and sulfinate and sulfonate esters, ethers, aldehydes, ketones, acids, amides, nitro derivatives, hydrophobic, hydrophilic and fluorophilic alkyl derivatives and polymers.

    Abstract translation: 本发明涉及福滨龙(卤代3-烷基-5-亚甲基-2(5 H) - 呋喃酮)及其合成类似物的侧链官能化,其产生在卤素,氧或氮官能团中被取代的菲莫拉林 烷基链,特别是曲芬洛尔醇,卡波西铵和亚磺酸盐和磺酸酯,醚,醛,酮,酸,酰胺,硝基衍生物,疏水性,亲水性和氟性烷基衍生物和聚合物。

    Process for the manufacture of pharmaceutical grade ranitidine base
    36.
    发明授权
    Process for the manufacture of pharmaceutical grade ranitidine base 失效
    制造药物级雷尼替丁碱的方法

    公开(公告)号:US5696275A

    公开(公告)日:1997-12-09

    申请号:US265308

    申请日:1994-06-24

    CPC classification number: C07D307/52

    Abstract: A process for the manufacture of pharmaceutical grade ranitidine base(N-�2-���5-(Dimethylamino)methyl!-2-furanyl!methyl!thio!ethyl-N'-methyl-2-nitro-1, 1-ethenediamine), is described. In-vitro and in-vivo pharmacological studies and acute toxicity studies indicate that it is as active and as safe as Form 2 ranitidine hydrochloride.

    Abstract translation: 制备药物级雷尼替丁碱(N- [2 - [[[5-(二甲基氨基)甲基] -2-呋喃基]甲基]硫基]乙基-N'-甲基-2-硝基-1,1- 乙烯二胺)。 体外和体内药理学研究和急性毒性研究表明,它与盐酸盐酸雷尼替丁的活性和安全性一样。

    System and method for billing system interface failover resolution
    38.
    发明授权
    System and method for billing system interface failover resolution 有权
    计费系统接口故障切换解决方案的系统和方法

    公开(公告)号:US08126958B2

    公开(公告)日:2012-02-28

    申请号:US13189524

    申请日:2011-07-24

    Abstract: A determination is made whether a first application server of a group of N application servers, N being at least two, is a coordinator of the group. Responsive to determining that the first application server is the coordinator of the group, a connection to a billing system is established, via a terminal server, by the first application server. A determination is made whether a second application server of the group of N application servers is the coordinator of the group. Responsive to determining that the second application server is not the coordinator of the group, a periodic check is made whether the second application server of the group of N application servers is the coordinator of the group. The second application server may later be determined to be the coordinator of the group, when the first server experiences difficulty. Once it is determined that the second application server now is the coordinator of the group, a connection is established to the billing system, via the terminal server, by the second application server.

    Abstract translation: 确定一组N个应用服务器的第一应用服务器是否为该组的协调器,N至少为两个。 响应于确定第一应用服务器是该组的协调器,通过终端服务器由第一应用服务器建立与计费系统的连接。 确定N个应用服务器组的第二应用服务器是否是该组的协调器。 响应于确定第二应用服务器不是组的协调器,定期检查N个应用服务器组中的第二应用服务器是否是该组的协调器。 当第一服务器遇到困难时,可以将第二应用服务器确定为该组的协调器。 一旦确定第二应用服务器现在是组的协调器,则通过第二应用服务器经由终端服务器向计费系统建立连接。

    MUSCARINIC RECEPTOR ANTAGONISTS
    39.
    发明申请
    MUSCARINIC RECEPTOR ANTAGONISTS 审中-公开
    肌肉受体拮抗剂

    公开(公告)号:US20100144801A1

    公开(公告)日:2010-06-10

    申请号:US12443838

    申请日:2007-10-02

    CPC classification number: C07D233/64 C07D211/70 C07D213/30

    Abstract: The present invention generally relates to muscarinic receptor antagonists of formula I, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors. Formula (I) wherein Het: is heterocyclyl or heteroaryl X: O, S or NR1 and the other substituents are defined as in the claims.

    Abstract translation: 本发明一般涉及式I的毒蕈碱受体拮抗剂,其可用于治疗通过毒蕈碱受体介导的呼吸,泌尿和胃肠系统的各种疾病,以及其它用途。 本发明还涉及制备所公开的化合物的方法,含有所公开的化合物的药物组合物,以及用于治疗通过毒蕈碱受体介导的疾病的方法。 式(I)其中Het:是杂环基或杂芳基X:O,S或NR1,其它取代基如权利要求中所定义。

Patent Agency Ranking